Will Sovaldi & Harvoni’s super-low distribution margins be addressed this year?
Gilead has attracted attention of the pharmaceutical distribution industry as planning to review the problem in distribution margins of ‘Sovaldi’ and ‘Harvoni,’ chronic hepatitis C treatments, which have super-low margins; it was known they are so low that the industry gets more deficits as selli...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
